New research suggests the diabetes drug metformin may be linked to a lower risk of developing intermediate age-related macular degeneration among older adults with diabetes, based on routine eye screening photos tracked over five years.
Researchers at the University of Liverpool examined retinal images from roughly 2,000 people receiving standard diabetic eye checks and tracked changes over a five-year span. They specifically looked for signs of intermediate age-related macular degeneration, or AMD, and graded how severe each case appeared. The analysis compared outcomes for patients taking metformin with those who were not on the drug.
The main headline finding was striking: participants over age 55 with diabetes who took metformin were about 37% less likely to develop intermediate AMD during the study period than those not taking the medication. That association held after the team adjusted for basic confounders such as age, sex, and how long a person had lived with diabetes. Still, observational research can reveal links without proving direct cause and effect.
The investigators emphasized that their work comes from routine clinical images rather than a randomized experiment, and they urged caution in interpreting the results. Differences in health behavior, other medications, or unmeasured factors could play a role in the observed benefit. The study also lacked detailed data on exact metformin dosages or how consistently participants took their prescriptions.
Crucially, the research focused only on people already living with diabetes, so it does not tell us whether metformin would offer the same protective signal in people without diabetes. That makes it premature to assume the drug is broadly protective against AMD in the general population. More targeted research is needed before any treatment recommendations could change.
Lead researcher Nick Bear reflected on the potential implications while stressing the need for testing. “Most people who suffer from AMD have no treatment, so this is a great breakthrough in our search for new treatments,” said Nick Bear, an ophthalmologist at the University of Liverpool in the U.K., who led the research. “What we need to do now is test metformin as a treatment for AMD in a clinical trial. Metformin has the potential to save many people’s sight,” he added.
Metformin is a low-cost, off-patent medication widely used to manage blood sugar in type 2 diabetes, which makes it an attractive candidate for repurposing if the protective effect is real. The medicine is known to have anti-inflammatory effects and has been studied for possible anti-aging actions, which could plausibly influence retinal health over time. Those biological ideas offer a potential mechanism but are not proof of benefit in people with or without diabetes.
Clinicians and patients should also weigh safety considerations even for an established drug like metformin. Major medical sources note that metformin is generally well tolerated, but some people experience digestive side effects and the medication can contribute to vitamin B12 deficiency in certain cases. Any move toward off-label use for eye disease would require careful monitoring and clearer evidence from clinical trials.
The next practical step, according to the authors, is to run randomized clinical trials that specifically test whether metformin can prevent or slow AMD progression. Trials could clarify appropriate dosing, treatment duration, and whether benefits extend beyond people with diabetes. A properly designed randomized study would also reduce the influence of confounding factors that can bias observational findings.
For now, the Liverpool research adds to a growing conversation about repurposing well-known drugs for age-related conditions, using real-world clinical data as an initial screen. It highlights how routine health screenings can generate useful research signals when paired with careful analysis. But it also underlines the limits of observational data and the need to follow up promising associations with controlled trials.
Patients with diabetes curious about metformin and eye health should not change their medications without talking to their doctor. Eye screening remains essential for early detection of diabetic eye disease and AMD symptoms. Health decisions should be guided by a clinician who can weigh individual risks, current evidence, and alternative treatment options.
Researchers hope the new findings will spur clinical trials and further investigation into how metabolic drugs affect the aging retina. If validated, a low-cost treatment that slows AMD could have major public health implications given an aging population and the high burden of vision loss. Until then, the results are encouraging but preliminary, pointing toward new research rather than immediate treatment changes.
